文献速递糖尿病

韩国全国队列:新诊断2型糖尿病使用DPP-4抑制剂与胰腺炎及胰腺癌风险趋势

Nationwide Trends in Pancreatitis and Pancreatic Cancer Risk Among Patients With Newly Diagnosed Type 2 Diabetes Receiving Dipeptidyl Peptidase 4 Inhibitors.
PubMed 文献 · Diabetes Care · 2019-08-20

该研究基于韩国国民健康保险筛查队列(n=514,866),纳入2007至2013年新诊断并接受降糖药治疗的2型糖尿病患者33,208例,其中DPP-4抑制剂新使用者10,218例,其他降糖药新使用者22,990例。采用含时变协变量的Cox比例风险模型,并设6个月滞后时间,发现DPP-4抑制剂使用者胰腺炎风险(aHR 1.24,95%CI 1.01-1.52;P=0.037)和胰腺癌风险(aHR 1.81,95%CI 1.16-2.82;P=0.009)显著增加;但风险在初始处方后12个月内及1年后基本一致,未随暴露时间延长而增加趋势,提示可能存在反向因果。

要点

  • DPP-4抑制剂使用与胰腺炎风险增加相关(aHR 1.24,95%CI 1.01-1.52;P=0.037)。
  • DPP-4抑制剂使用与胰腺癌风险增加相关(aHR 1.81,95%CI 1.16-2.82;P=0.009)。
  • 风险未随用药时间延长而增加,提示反向因果可能,需长期胰腺安全性研究。

核心结论

  • 在新诊断2型糖尿病患者中,DPP-4抑制剂使用与胰腺炎和胰腺癌风险增加相关。
  • 风险未随暴露时间延长而增加趋势,提示可能存在反向因果,长期胰腺安全性需进一步研究。

研究设计与样本

  • 韩国全国性人群队列研究,数据来自韩国国民健康保险服务-健康筛查队列数据库(n=514,866)。
  • 纳入2007至2013年新诊断并接受降糖药治疗的2型糖尿病患者33,208例。
  • DPP-4抑制剂新使用者10,218例,其他降糖药新使用者22,990例。
  • 采用含时变协变量的Cox比例风险模型估计风险,并设6个月滞后时间。

主要发现

  • DPP-4抑制剂使用者胰腺炎风险显著增加(aHR 1.24,95%CI 1.01-1.52;P=0.037)。
  • DPP-4抑制剂使用者胰腺癌风险显著增加(aHR 1.81,95%CI 1.16-2.82;P=0.009)。
  • 初始处方后12个月内及1年后的胰腺炎和胰腺癌风险基本一致,未随暴露时间延长而增加。

临床怎么用

  • 对新诊断2型糖尿病患者处方DPP-4抑制剂时,应关注胰腺炎和胰腺癌风险信号。
  • 用药期间若出现胰腺相关症状,需警惕并及时评估。
  • 鉴于反向因果可能,不宜仅凭本研结果改变临床决策,应结合个体获益风险。

局限性

  • 观察性研究设计,无法排除残余混杂和反向因果。
  • 风险未随暴露时间增加,提示结果解释需谨慎,长期安全性需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Dipeptidyl peptidase 4 inhibitors (DPP-4i) are useful incretin-based antidiabetes drugs. However, there is a concern that DPP-4i may adversely impact the exocrine pancreas, owing to their pleiotropic effects. In this study, we investigated whether DPP-4i are associated with pancreatitis and pancreatic cancer using a nationwide population-based cohort study. RESEARCH DESIGN AND METHODS: We included patients newly diagnosed with type 2 diabetes who were treated with antidiabetes drugs (n = 33,208) from 2007 to 2013. The data were obtained from the Korean National Health Insurance Service-Health Screening Cohort database (n = 514,866). Risk was estimated using a Cox proportional hazards model with time-dependent covariates. A 6-month lag time was used to account for a possible latency time. The risk across various time segments since the first prescription of DPP-4i was also analyzed. RESULTS: Out of 33,208 subjects, 10,218 were new users of DPP-4i and 22,990 were new users of other antidiabetes drugs. DPP-4i significantly increased the risks of pancreatitis (adjusted hazard ratio [aHR] 1.24, 95% CI 1.01-1.52; P = 0.037) and pancreatic cancer (aHR 1.81, 95% CI 1.16-2.82; P = 0.009) with a 6-month drug use lag period. The risk of pancreatitis and pancreatic cancer was generally consistent in the first 12 months and 1 year after the initial prescription without showing an increasing trend according to exposure duration. CONCLUSIONS: DPP-4i use is associated with increased risks of pancreatitis and pancreatic cancer in patients with newly diagnosed type 2 diabetes. However, the absence of increasing trend according to exposure duration suggests the chances of reverse causality, and long-term pancreatic safety of DPP-4i has to be further investigated.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Lee M, Sun J, Han M, et al. Nationwide Trends in Pancreatitis and Pancreatic Cancer Risk Among Patients With Newly Diagnosed Type 2 Diabetes Receiving Dipeptidyl Peptidase 4 Inhibitors. Diabetes Care. 2019. PMID: 31431452. doi:10.2337/dc18-2195

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。